Article
Oncology
Kaeli Singer, Charlotte M. M. Forshay, Julie Kennerly-Shah
Summary: This study compared the inpatient cost of daily filgrastim to single dose pegfilgrastim and biosimilars, and determined the number and duration of discharge prescriptions for filgrastim.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2023)
Article
Medicine, General & Internal
Douglas W. Blayney, Ramon Mohanlal, Hryhoriy Adamchuk, Dmitry Valikovich Kirtbaya, Michael Chen, Lihua Du, Stephan Ogenstad, Greg Ginn, Lan Huang, Qingyuan Zhang
Summary: The study demonstrated that plinabulin is noninferior to pegfilgrastim in preventing chemotherapy-induced neutropenia in patients with solid tumors, showing better safety and immunosuppressive profile. Plinabulin's same-day dosing had distinct advantages in reducing healthcare services compared to pegfilgrastim's next-day dosing.
Article
Immunology
Allen W. Zhang, Sejal Morjaria, Anna Kaltsas, Tobias M. Hohl, Rekha Parameswaran, Dhruvkumar Patel, Wei Zhou, Jacqueline Predmore, Rocio Perez-Johnston, Justin Jee, Anthony F. Daniyan, Miguel-Angel Perales, Ying Taur
Summary: The use of G-CSF in cancer patients with COVID-19 may increase the risk of hospitalization, respiratory failure, and death. Careful consideration should be given to the potential risks and benefits of G-CSF treatment in neutropenic cancer patients with COVID-19.
CLINICAL INFECTIOUS DISEASES
(2022)
Article
Radiology, Nuclear Medicine & Medical Imaging
Atsushi Takamatsu, Kotaro Yoshida, Fumihito Toshima, Kazuto Kozaka, Naho Yamamoto, Yoshimichi Sai, Toshifumi Gabata
Summary: This study aims to clarify the incidence and clinicoradiologic characteristics of pegfilgrastim-induced aortitis. The results of the study found that the incidence of pegfilgrastim-induced aortitis may be higher than previously reported and may be more common in patients with esophageal cancer and those who received specific anticancer drugs. Furthermore, CT findings indicated that pegfilgrastim-induced aortitis is often characterized by involvement of the aortic arch and proximal branches.
Review
Dermatology
J. Karim Ead, David G. Armstrong
Summary: GM-CSF is a glycoprotein with immunomodulatory properties derived from both hemopoietic and nonhemopoietic sources. In patients with diabetic foot ulcers, GM-CSF activation is impaired, leading to impaired inflammatory response. Correcting macrophage immune dysfunction with exogenous GM-CSF may help restore immune balance and promote wound healing.
INTERNATIONAL WOUND JOURNAL
(2023)
Review
Oncology
Zhixuan You, Haotian Zhang, Yining Huang, Lei Zhao, Hengjia Tu, Yuzhuo Zhang, Xinqing Lin, Wenhua Liang
Summary: Patients with breast cancer undergoing chemotherapy are at risk of prolonged and severe neutropenia. Multiple biosimilars of long-acting granulocyte colony-stimulating factors (LA-G-CSFs) have been developed to prevent this condition. However, the optimal LA-G-CSF regimen remains controversial. Moreover, there is a lack of evidence supporting clinical decisions on LA-G-CSF dose escalation in poor conditions. Our research findings suggest that certain LA-G-CSFs perform better than others and increasing the dosage may enhance efficacy without additional severe adverse events.
Article
Oncology
Angelo Borsarelli Carvalho de Brito, Rachel P. Riechelmann, Victor Hugo Fonseca de Jesus
Summary: This study examined the impact of primary prophylaxis (PP) with granulocyte colony-stimulating factor (G-CSF) on the frequency of neutropenia and survival outcomes in patients with metastatic pancreatic adenocarcinoma (MPA) treated with FOLFIRINOX. The results showed that although the frequency of grade 3/4 neutropenia decreased, the risk of febrile neutropenia (FN) was low in the FOLFIRINOX treatment group without G-CSF, and it was not justified for routine use. However, further studies are needed to assess the potential role of G-CSF in improving survival in MPA patients treated with FOLFIRINOX.
Review
Clinical Neurology
Mahsa Vafaei Mastanabad, Aref Nooraei, Mahgol Sadat Hassan Zadeh Tabatabaei, Amir Akbari Fakhrabadi, Faria Jafarzadeh
Summary: This article introduces the basics of amyotrophic lateral sclerosis (ALS) and G-CSF, and comprehensively reviews the applications of G-CSF in clinical and pre-clinical studies, emphasizing the significant efficacy in pre-clinical studies and the failure to replicate the results in clinical studies.
ACTA NEUROLOGICA BELGICA
(2023)
Editorial Material
Oncology
Claudio Cerchione, Davide Nappi, Alessandra Romano, Giovanni Martinelli
Summary: This article provides a brief summary of the efficacy and safety of using pegfilgrastim as primary prophylaxis in HL during chemotherapy treatment.
Article
Oncology
Lauren Roder, Kelsey Konrardy, Dennis Grauer, Marc Hoffmann
Summary: The study aimed to compare the dose levels reached with DA-R-EPOCH using filgrastim versus pegfilgrastim for febrile neutropenia prophylaxis, finding similar efficacy and safety outcomes between the two agents in terms of dose intensity levels and incidence of infections, febrile neutropenia, and bone pain.
SUPPORTIVE CARE IN CANCER
(2021)
Article
Biotechnology & Applied Microbiology
Xu-Dong Wang, Wei-Jia Yu, Jia-Hui Liu, Jie Du, Kang-Nan Chen, Qin-Qin Hu, Wen-Long Sun, Guo-Qing Ying
Summary: This study investigated a long-acting strategy for modifying rhG-CSF with C15-MAL, which significantly increased its serum half-life and showed potential as a novel drug candidate. The modified C15-rhG-CSF retained its bioactivity and demonstrated improved efficacy compared to other existing treatments.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY
(2022)
Article
Neurosciences
Lillian J. Brady, Kirsty R. Erickson, Kelsey E. Lucerne, Aya Osman, Drew D. Kiraly, Erin S. Calipari
Summary: Cocaine use disorder is associated with alterations in immune function and changes in peripheral cytokine expression, impacting responses to drug-related cues and highlighting the critical interaction between the brain and immune system. Upregulation of granulocyte colony-stimulating factor (G-CSF) by cocaine enhances the drug's effects on dopamine terminals through a release-based mechanism, indicating a potential role of immune factors in altering drug responses.
PSYCHOPHARMACOLOGY
(2021)
Article
Pharmacology & Pharmacy
Aaron W. Stewart, Alexandra Shillingburg, William Petros, Sijin Wen, Debra Piktel, Rebecca Moses, Laura F. Gibson, Michael Craig, Aaron Cumpston
Summary: Calculating subcutaneous filgrastim doses using actual body weight appears to produce similar systemic exposure in morbidly obese and non-obese patients with severe neutropenia, with no significant differences in specific pharmacokinetic parameters (such as clearance, area under the curve, maximum concentration, etc.) between the two groups.
Editorial Material
Radiology, Nuclear Medicine & Medical Imaging
Koji Tokunaga, Chikara Maeda, Sadao Horikawa, Ryuko Nakayama, Shigeaki Umeoka
Summary: We present a case of G-CSF-producing inflammatory myofibroblastic tumor in a 71-year-old man with multiple pleural masses and pulmonary hilar lymph nodes swelling. Imaging studies showed focal FDG uptake in the thoracic masses and diffuse uptake in the bone marrow. Based on pathology and elevated serum G-CSF level, the patient was diagnosed with G-CSF-producing inflammatory myofibroblastic tumor. Early and accurate diagnosis is crucial due to the aggressive clinical course of G-CSF-producing tumors.
CLINICAL NUCLEAR MEDICINE
(2023)
Article
Oncology
Takeo Fujii, Hasan Rehman, Su Yun Chung, Janice Shen, James Newman, Vernon Wu, Adam Hines, Elham Azimi-Nekoo, Fatima Fayyaz, Meeyoung Lee, George Raptis, Mikala Egeblad, Xinhua Zhu
Summary: The study found that G-CSF use was not associated with an increased risk of brain metastasis in patients with de novo Stage IV breast cancer. However, pulmonary embolism/deep venous thrombosis may be related to brain metastasis. Further research is needed to determine if DVT/PE with or without elevated NETs levels in the blood can predict the development of brain metastasis in these patients.